March 2016

Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast

Author Affiliations
  • 1University of Arizona College of Medicine, Tucson
  • 2Department of Dermatology, University of Arizona, Tucson

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2016;152(3):348-350. doi:10.1001/jamadermatol.2015.3405

Pityriasis rubra pilaris (PRP) is an inflammatory dermatologic disorder of unknown cause characterized by hyperkeratotic follicular papules combining into salmon-colored scaling plaques, palmoplantar hyperkeratosis, and sharply demarcated islands of spared skin.1 We report a case of refractory PRP treated with the immune modulator apremilast.

A white man in his 70s presented with an 8-month history of scaling, pink, pruritic papules, originating on his back (Figure, A), which coalesced to encompass nearly his entire body surface. There was extensive erythema with scaling and waxy, hyperkeratotic scaling of the palms and soles.

First Page Preview View Large
First page PDF preview
First page PDF preview